CDH1 and prostate cancer: When SETD2 is deficient, it inhibits the expression of the epithelial marker E-cadherin, while upregulating the expression of mesenchymal markers N-cadherin and Vimentin, which promotes the EMT of prostate cancer cells, so that the cells acquire a stronger migratory and invasive ability and thus become prone to metastasis.